Recent Updates
Recently added Catalysts
LXRX Positive Sentiment

Lexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026

Key Takeaway: Lexicon Pharmaceuticals will release its second quarter 2026 financial results on August 6, 2026, before market opening. A conference call and live webcast will be held at 8:30 a.m. ET to discuss the results and provide a business update. Interested participants can access the call via the company's website.
Price reaction · baseline $2.32 (2026-07-29 close) · hit pre-market · clean, no other LXRX news in the window
day 0 close · peak
+0.9%

Market Sentiment Analysis

POSITIVE FACTORS

  • Lexicon Pharmaceuticals is actively engaging with investors.
  • The company has a diverse pipeline in various therapeutic areas.
  • The upcoming financial results may provide insights into the company's performance.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+111%
120-day peak, hindsight
Typical move
8%
average across 8 past catalysts
Cash runway
~60 mo
Minimal dilution risk
Lead asset
LX9211
Phase 2 · Postherpetic Neuralgia

Full Press Release Details

THE WOODLANDS, Texas, July 30, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its second quarter 2026 financial results on Thursday, August 6, 2026, prior to market open. Management will conduct a conference call and live webcast at 8:30 a.m. ET (7:30 a.m. CT) that day to discuss the financial results and to provide a business update.
Participants can access the conference call live via webcast on the Events page of the Company’s website at https://investors.lexpharma.com/. Participants who wish to ask a question may register here to receive dial-in numbers and a unique pin to join the call. An archived version of the webcast will be available on the Lexicon website.
About Lexicon Pharmaceuticals Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ lives. Lexicon has a pipeline of drug candidates in discovery, preclinical, and clinical development in neuropathic pain, hypertrophic cardiomyopathy (HCM), obesity and metabolic disorders, and other cardiometabolic indications. For additional information, please visit www.lexpharma.com.

For Media Inquiries: Dave Belian Lexicon Pharmaceuticals, Inc. lexinvest@lexpharma.com

For Investor Inquiries: Lisa DeFrancesco Lexicon Pharmaceuticals, Inc. lexinvest@lexpharma.com

Frequently Asked Questions

When will Lexicon Pharmaceuticals report its Q2 2026 results?

Lexicon Pharmaceuticals will report its Q2 2026 financial results on August 6, 2026.

What time is the conference call for Q2 2026 results?

The conference call will take place at 8:30 a.m. ET on August 6, 2026.

How can I access the conference call?

Participants can access the call via the Events page on Lexicon's website.

What topics will be discussed during the conference call?

The call will discuss financial results and provide a business update.

Last updated: Jul 30, 2026